Search
for
Sort by
Research
870-900 / 1000+ results
research Supplementary Material for: Drug-Induced Melasma in Patients on 5-Alpha Reductase Inhibitors: A Case Report
Finasteride can cause melasma, especially in people with darker skin.
research Monilethrix treated with oral retinoids
Oral etretinate improved hair length and reduced beading in monilethrix.
research Clinical and hormonal effects of the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism.
Finasteride reduces hair growth and is safe for women with excessive hair.
research Inhibition of the pro-oxidant effects of benoxaprofen on poiymorpbonuclear leucocytes by retinol acetate in vitro
Retinol acetate can reduce the harmful effects of the drug benoxaprofen on white blood cells.
research Adverse Effects of the 5-Alpha-Reductase Inhibitor Finasteride on Daphnia Magna: Endocrine System and Lipid Metabolism Disruption
Finasteride harms Daphnia magna's reproduction and metabolism.
research Comparison of finasteride versus flutamide in the treatment of hirsutism
Finasteride is a safe, effective treatment for hirsutism with fewer side effects.
research Food Administration and Not Genetic Variants Causes Pharmacokinetic Variability of Tadalafil and Finasteride
Food intake, not genetics, affects how the body processes tadalafil and finasteride.
research Excess salt and pepper hair treated with a combination of laser hair removal and topical eflornithine HCl.
Combining laser hair removal with a cream effectively reduced facial hair.
research Epidermal growth factor receptor inhibitors and hair
research Widespread skin hypopigmentation caused by finasteride when used for female hirsutism
Finasteride can cause lasting skin lightening in women.
research Depression, suicidal thoughts with finasteride (Propecia)
Finasteride (Propecia) may cause depression and suicidal thoughts; stop use and inform a healthcare professional if symptoms develop.
research Finasteride
Finasteride treats enlarged prostate, improves urinary flow, but may cause sexual side effects.
research Bioequivalent Assessment of Finasteride Granules in Chinese Healthy Volunteers
Finasteride granules and tablets work the same in the body.
![Patent Evaluation: Hexahydrobenzo[f]quinolines as 5α-Reductase Inhibitors](/images/research/1634373b-f615-46c7-a157-21394e3366be/small/21095.jpg)
research Patent Evaluation: Hexahydrobenzo[f]quinolines as 5α-reductase inhibitors
Hexahydrobenzo[f]quinolines are effective at blocking the enzyme 5α-reductase.
research Analysis of Adverse Drug Reactions in Pediatric Patients with Epilepsy: An Intensive Pharmacovigilance Study
Many pediatric epilepsy patients experience preventable severe adverse drug reactions, especially with certain medications and risk factors.
research Post-finasteride syndrome
Post-finasteride syndrome causes sexual, physical, and psychological symptoms, but more research is needed to understand its causes and connection to finasteride.
research Neuroactive steroids induce changes in fetal sheep behavior during normoxic and asphyxic states
Neurosteroids help protect fetal brains from asphyxia damage.
research Cardiovascular Safety Signals of Oral Versus Topical Minoxidil in FAERS: A Disproportionality Analysis (Analytic Cohort 2012–2025)
Oral minoxidil may have more cardiovascular risks than topical minoxidil.
research RETRACTED: Fabrication of Oro-Dispersible Sodium Valproate-Loaded Nanofibrous Patches for Immediate Epileptic Innervation
research Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration’s adverse event reporting system databases
This study analyzed 23,542 adverse event reports related to gepant medications for migraine treatment from the VigiAccess and FDA databases, focusing on rimegepant, atogepant, and ubrogepant. Rimegepant had the highest incidence of gastrointestinal adverse events, particularly nausea, and was associated with skin disorders like rash and pruritus, as well as alopecia, which was identified as a novel and more severe adverse event. Cardiac adverse events were similar across gepants, but rimegepant had the strongest signals, while ubrogepant showed more musculoskeletal adverse events. The study emphasizes the need for personalized treatment and monitoring of adverse events based on individual patient characteristics, highlighting the importance of understanding the safety profiles of these drugs in real-world settings.
research Comparing minoxidil-finasteride mixed solution with minoxidil solution alone for male androgenetic alopecia: a systematic review and meta-analysis of randomized controlled trials
The minoxidil-finasteride combination is more effective for hair growth than minoxidil alone.
research Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men
research Where it all went right
Some drugs have gained approval for new uses, while others like tricyclic antidepressants and aspirin show promise but aren't yet approved for these uses.
research Telogen effluvium associated with eosinophilia-myalgia syndrome
Hair loss in a woman with eosinophilia-myalgia syndrome improved after stopping L-tryptophan and starting treatment.
research THE ROLE Of 5αR AND α1AR INHIBITORS IN MANAGEMENT OF BPH
Combining dutasteride or finasteride with an α1 blocker is more effective for managing BPH than using either alone.
research Interaction of chronic ethanol exposure and finasteride: sex and strain differences
Finasteride reduces alcohol withdrawal effects, especially in female mice.
research STABILITY-INDICATING MICELLAR ELEKTROKINETIC CHROMATOGRAPHY METHOD FOR DETERMINATION OF FINASTERIDE IN PHARMACEUTICAL PREPARATIONS
Method accurately measures finasteride concentration in medicine.
research 62339 Improvement in anxiety and depression in adult patients with severe alopecia areata treated with deuruxolitinib: Pooled data from the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials
Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.
research Pharmacological Profile of 9,11-Dehydrocortexolone 17α-Butyrate (CB-03-04), a New Androgen Antagonist with Antigonadotropic Activity
CB-03-04 shows promise as a treatment for prostate issues due to its strong anti-androgen effects.